Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2025-2031) | Industry, Trends, Competitive Landscape, Value, Companies, Analysis, Size & Revenue, Outlook, Segmentation, Growth, Share, Forecast

Name: Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market (2025-2031) | Industry & Trends
Creator: 6Wresearch
License: https://www.6wresearch.com/privacy-policy

Market Forecast By GLP-1 Receptor Agonists (Exenatide, Liraglutide (Victoza), Lixisenatide (Lyxumia), Dulaglutide (Trulicity), Semaglutide (Ozempic)), By Insulin Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins) And Competitive Landscape

Product Code: ETC8259534	Publication Date: Sep 2024	Updated Date: Nov 2025	Product Type: Market Research Report
Publisher: 6Wresearch	Author: Vasudha	No. of Pages: 75	No. of Figures: 35	No. of Tables: 20

Mauritius Insulin Drugs And Glucagon Like Peptide 1 Glp 1 Receptor Agonist Market Top 5 Importing Countries and Market Competition (HHI) Analysis

The import shipments of insulin drugs and GLP-1 receptor agonists to Mauritius in 2024 show a diversification in sources, with top exporting countries being India, Metropolitan France, Germany, Turkey, and the UK. The market concentration, as measured by the HHI, decreased from high to moderate in 2024, indicating a more balanced distribution among suppliers. Despite a slight decline in growth rate from 2023 to 2024, the compound annual growth rate (CAGR) for the period 2020-2024 stands at a healthy 4.71%, reflecting steady demand and market stability in Mauritius for these pharmaceutical products.

Mauritius Insulin Drugs And Glucagon Like Peptide 1 Glp 1 Receptor Agonist Market Top 5 Importing Countries and Market Competition (HHI) Analysis

Key Highlights of the Report:

Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Outlook
Market Size of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, 2024
Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Revenues & Volume for the Period 2021- 2031
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Trend Evolution
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Drivers and Challenges
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Price Trends
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Porter's Five Forces
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Industry Life Cycle
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By GLP-1 Receptor Agonists for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Exenatide for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Liraglutide (Victoza) for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Lixisenatide (Lyxumia) for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Dulaglutide (Trulicity) for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Semaglutide (Ozempic) for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Insulin Drugs for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Basal or Long-acting Insulins for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Bolus or Fast-acting Insulins for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Traditional Human Insulins for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Combination Insulins for the Period 2021- 2031
Historical Data and Forecast of Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume By Biosimilar Insulins for the Period 2021- 2031
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Import Export Trade Statistics
Market Opportunity Assessment By GLP-1 Receptor Agonists
Market Opportunity Assessment By Insulin Drugs
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Top Companies Market Share
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Competitive Benchmarking By Technical and Operational Parameters
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Company Profiles
Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Key Strategic Recommendations

Frequently Asked Questions About the Market Study (FAQs):

How does 6Wresearch market report help businesses in making strategic decisions?

Do you also provide customisation in the market study?

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Overview

3.1 Mauritius Country Macro Economic Indicators

3.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, 2021 & 2031F

3.3 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Industry Life Cycle

3.4 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Porter's Five Forces

3.5 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By GLP-1 Receptor Agonists, 2021 & 2031F

3.6 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume Share, By Insulin Drugs, 2021 & 2031F

4 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of diabetes in Mauritius

4.2.2 Growing awareness about diabetes management and treatment options

4.2.3 Technological advancements in insulin drugs and GLP-1 receptor agonists

4.3 Market Restraints

4.3.1 High cost of insulin drugs and GLP-1 receptor agonists

4.3.2 Limited access to healthcare services in certain regions of Mauritius

4.3.3 Regulatory challenges and approval processes for new medications

5 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Trends

6 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Types

6.1 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By GLP-1 Receptor Agonists

6.1.1 Overview and Analysis

6.1.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By GLP-1 Receptor Agonists, 2021- 2031F

6.1.3 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Exenatide, 2021- 2031F

6.1.4 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Liraglutide (Victoza), 2021- 2031F

6.1.5 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Lixisenatide (Lyxumia), 2021- 2031F

6.1.6 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Dulaglutide (Trulicity), 2021- 2031F

6.1.7 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Semaglutide (Ozempic), 2021- 2031F

6.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market, By Insulin Drugs

6.2.1 Overview and Analysis

6.2.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Basal or Long-acting Insulins, 2021- 2031F

6.2.3 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Bolus or Fast-acting Insulins, 2021- 2031F

6.2.4 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Traditional Human Insulins, 2021- 2031F

6.2.5 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Combination Insulins, 2021- 2031F

6.2.6 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenues & Volume, By Biosimilar Insulins, 2021- 2031F

7 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Import-Export Trade Statistics

7.1 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Export to Major Countries

7.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Imports from Major Countries

8 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Key Performance Indicators

8.1 Patient adherence rate to prescribed insulin and GLP-1 receptor agonists

8.2 Number of healthcare facilities offering diabetes management services

8.3 Percentage of diabetic population in Mauritius achieving target glycemic control markers

9 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Opportunity Assessment

9.1 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By GLP-1 Receptor Agonists, 2021 & 2031F

9.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Opportunity Assessment, By Insulin Drugs, 2021 & 2031F

10 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market - Competitive Landscape

10.1 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Revenue Share, By Companies, 2024

10.2 Mauritius Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Croatia Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Cuba Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Cyprus Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Denmark Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market

Global Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market